the other pharmaceutical, as preventive health care technologies lets us see gender and sexuality in new ways, especially as they relate to chil dren's bodies.
Although feminist STS offers insights about gender and technology, our sociological analysis of containment offers a more complex examination of how gender's intersections with race, class, age, and sexuality position technologies and responses to them (also see Casper and Carpenter 2008) .
Here and in our broader project, we reveal how sexual and reproductive health practices unfold in the shifting context of contemporary U.S. bio politics (Rose 2006) . We ask, how have cultural understandings of sexu ality, gender, age, race, and nationality-and their interrelations-shaped responses to the two technologies? Why have attempts to mandate HPV vaccination activated concerns about female promiscuity, whereas talk of promoting circumcision as HIV preventive for boys has not (at least regar ding U.S. boys)? How, in turn, might uptake of the HPV vaccine and the reframing of circumcision against HIV alter social constructions not only of gender and sexuality but also of age and race? Our focus is on the United
States, but these deeply stratified processes have transnational implications (Carpenter and Casper 2009 ), insofar as American responses to the tech nologies also influence practices in the developing world.
Technologies such as the HPV vaccine are not therapeutic; rather, they are designed to prevent the onset of disease through containment of causal infection. The phenomena we have called "pharmacologies of contain ment" (Casper and Carpenter 2008) are implicated in the broader politics of contagion, which inevitably invoke intimacies shared among people. The threat of contagion-the transmissibility of disease-motivates "the establishment of cordons sanitaire in one form or another, the drawing of lines and zones of hygiene" (Bashford and Hooker 2001, 9) . In our view, the HPV vaccine is a highly politicized pharmaceutical cordon sanitaire, formed within particular social, economic, and geographic contexts. It embodies the "dream of hygienic containment" (Bashford and Hooker 2001) and as such has activated social cleavages related to gender, sex, race, age, and especially sexuality. As Brandt (1987, 5) notes, "Since the late nineteenth century, venereal disease has been used as a symbol for a society characterized by a corrupt sexuality . . . as a symbol of pollution and contamination." differ in important conceptual and practical ways. Our feminist sociologi cal analysis broadens notions of containment by asking under what struc tural and symbolic conditions such strategies work (or do not). Although a significant public health and clinical literature on nonvaccine containment technologies exists, as do histories of medicine and health focused on con tagion (e.g., Anderson 2003; Bashford and Hooker 2001; Brandt 1987) , social analyses of nonpharmaceuticals qua hygienic containment technolo gies are lacking. Seeking conceptual innovation, we ask, how do social relations shape containment efforts as technologies are (re)invented? Whose bodies, fluids, and sexual practices need to be contained, when, by whom, and for what purposes? How do pharmaceutical and surgical containment strategies discipline some bodies and not others?
Our comparative examination of two different contexts of sexual con tainment holds particular promise for advancing the sociology of contain ment. Sexual beliefs and conduct have long been interpreted and assessed differently depending on the gender, race or ethnicity, social class, age, and nationality of the sexual actors in question (Brandt 1987) . Men, peo ple of color (especially people of African descent), the economically dis advantaged, and individuals who experience or express same-sex desire have been stereotyped as sexually uncontrollable and in need of contain ment (Nathanson 1991; Roberts 1997; Seidman 2002; Tolman 1996) though considerable license is granted to white, heterosexual, middle-class men-while children and younger teenagers are typically viewed (depend ing on their race or ethnicity) as innocent and inherently asexual (Levine 2002) . Exactly who and what are contained by technologies such as cir cumcision and HPV vaccination may best be understood through an analy sis sensitive to intersectionality (Collins 1990) ; conversely, interrogating the dynamics of containment technologies can illuminate the workings of intersecting social statuses. We are especially keen to include men's bod ies and experiences in intersectional analysis (which all too often consid ers only women) and to explore emergent sites of containment where the "double standard" is both a strategically deployed cultural resource and an ongoing social accomplishment.
(RE)INTRODUCING THE TECHNOLOGIES
In 2006, with much fanfare, Merck & Co. announced U.S. Food and Drug Administration (FDA) approval of Gardasil, the first vaccine for HPV. Another similar HPV vaccine, Cervarix by GlaxoSmithKline, is cur rently undergoing FDA review. Composed of over 100 strains, including 30 transmissible by sex, HPV is the most common STI in the world. It is also the key agent of infection in CC, now viewed as an STI rather than a typical cancer; however, not all HPV leads to CC (Koushik and Franco 2006) . Globally, approximately 493,000 new cases of CC are diagnosed each year, representing 10 percent of all cancers in women (Koushik and Franco 2006) . Over 80 percent of new cases occur in developing countries (Dailard 2006) . In the United States, where screening is routine for most women, CC is relatively rare, yet morbidity and mortality from CC are higher among women of color and women from lower socioeconomic strata (Singh et al. 2004) .
Gardasil prevents infections from HPV-16 and HPV-18, two strains that cause about 70 percent of CCs, as well as which produce 90 percent of genital warts (Harper 2004; Harper et al. 2006) . Although publicly framed by their manufacturers as vaccines against CC, Gardasil and Cervarix can also protect women and men against anal, penile, and throat cancers caused by HPV (and transmitted through sex with male or female partners; Kubba 2008; Nack 2008) . Complication rates are low, under 2 percent in most studies, and side effects are generally minor, although more than 7,000 "adverse events" have been reported and safety remains a concern of many who oppose mandating widespread vac cination (CNN 2008; Wheeler 2007) .1 As we have demonstrated elsewhere (Casper and Carpenter 2008) , the HPV vaccine has shifted health care politics and sexual politics, and controversy surrounds its continued use.
The HPV vaccine is a profitable pharmaceutical commodity with a distinctive biography and life course. Where Van der Geest, Whyte, and Hardon (1996) see pharmaceutical biographies as unfolding in the context of politics, in our view politics is not merely context. Rather, at every stage of their life courses-production, marketing, distribution, prescrip tion, use, and efficacy-pharmaceuticals may influence politics and social relations, which in turn may (re)shape the technology itself. Drugs can instigate political struggles, and potentially social change, over time; for example, the birth control pill (Watkins 1998) , Viagra (Loe 2004) , and now the HPV vaccine (Casper and Carpenter 2008 ) embody social con flicts and shifting cultural values. As a containment technology targeting disease circulation among human beings, the vaccine evokes acute and longstanding politics of risk, danger, and bodily vulnerability.
Male circumcision is not a pharmaceutical vaccine but a surgical pro cedure for removing part or all the foreskin of the penis. Yet circumcision has served as a technology of containment in the United States since its medicalization in the late nineteenth century (Carpenter, forthcoming) .2 By the 1940s, about 60 percent of U.S. males were circumcised in infancy Carpenter, Casper / A TALE OF TWO TECHNOLOGIES 795 (Laumann, Masi, and Zuckerman 1997) . Supported by medical profession als and the for-profit insurance system, infant circumcision grew in popu larity until about 1970, when rates exceeded 90 percent, largely because of its purported ability to prevent STIs and "unhygienic" germs (it was widely, if erroneously, believed that intact penises are difficult to clean); circumcision also became a typical therapy for phimosis (unretractable foreskin). However, evidence that circumcision actually prevents STIs was, and is, mixed (Gollaher 2000) .
In the 1970s, following a cost-benefit analysis, the American Academy of Pediatrics (AAP) declared circumcision to be medically unnecessary. This move, representing a general decline in medical support-along with grassroots anticircumcision activism (on grounds including painfulness, human rights, and informed consent), the natural childbirth movement, cost cutting measures by health insurers, and immigration from locales where circumcision is rare-resulted in much lower rates of circumcision, about 65 percent by 1999 (Darby 2005; Gollaher 2000) . Since 1989, largely prompted by a vocal coterie of procircumcision physician-researchers, AAP has recognized "potential medical benefits" (chiefly the containment of urinary tract infections and penile cancer, which is exceedingly rare) but declined to recommend routine circumcision. Complication rates of infant circumcision in the United States are generally thought to be low, about 1 in 1,000. In short, use of circumcision for disease containment is contested, both within and outside the U.S. medical community; each "new" use of circumcision comes into already existing contexts of dissent.
Circumcision has recently been positioned as a potentially effective intervention against HIV/AIDS following clinical trials conducted in sub Saharan Africa, where HIV is contracted primarily via heterosexual vagi nal intercourse. Trials there found that circumcision of adult men reduces female-to-male HIV transmission rates by 30 percent to 50 percent (Auvert et al. 2005; Talbott 2007 ). Male circumcision has not proven effective in protecting women from heterosexually transmitted HIV infection, how ever (Altman 2008) . About 62 percent of adult men in Africa are circum cised, with rates varying widely by region and ethnic group (e.g., nearly universal among African Muslims but anathema among ethnic groups that view intact foreskins as a sign of cultural distinction). In southern Africa, where rates of HIV are highest, fewer than 20 percent of men are circum cised (see http://www3.niaid.nih.gov/news/QA/AMC 12_QA.htm). Across Africa, complication rates of circumcision are high-ranging from 18 per cent in public clinics to 35 percent among traditional practitioners-because of poor training and inadequate and/or unsanitary equipment (Maclnnis 2008 ).
The HIV/AIDS epidemic is less severe in the United States but still of great concern, given an infection rate of 13.7 per 100,000 population, with the highest rates among Blacks and Hispanics (54.1 and 18.0, respec tively; Centers for Disease Control and Prevention [CDC] 2007). Of U.S. men diagnosed with AIDS in 2006, 72 percent contracted the disease through male-to-male sexual contact and 9 percent through injection drug use; of women diagnosed in the same period, 20 percent contracted AIDS through injection drug use and 80 percent through heterosexual contact (CDC 2009 ). Just over 9,000 of the nearly one million U.S. citizens with AIDS as of 2007 were younger than 13 at diagnosis, suggesting that pre ventive intervention in or before early adolescence could be effective (CDC 2009 ). Since 2007, prompted by the African clinical trials, AAP has been reevaluating its position on infant circumcision (Konrad 2007) , while the CDC is considering policies for infants and adults (Rabin 2009 ).
Insofar as the vast majority of U.S. adult males are circumcised, "For now, the focus of public officials in this country appears to be on making rec ommendations for newborns" (Rabin 2009 ).
Although not a pharmaceutical, circumcision works like a relatively inefficient vaccine with respect to HIV. Virtually every vaccine fails to protect some of the people who receive it. However, vaccines recom mended by the U.S. Advisory Committee on Immunization Practices (ACIP; e.g., for polio, chicken pox) produce immune responses in 90 percent to 98 percent of individuals who receive them. If circumcision were a vaccine, the comparable figure based on the African trials would be 30 percent to 50 percent. Both HPV vaccination and circumcision, then, are preventive technologies inscribed in the body, with delayed benefits presumed to accrue long after the procedures themselves. Both operate according to principles of herd immunity; that is, performing the procedure on a certain proportion of people-typically about 70 percent-greatly reduces a disease's chances of spreading (Colgrove 2006) . The HPV vaccine and male circumcision are also similar in that they require individuals to assume embodied risks for later, perhaps invisible personal and collective benefits, something people in general dislike doing-although parents are more apt to consent to risks on behalf of their children for the sake of prevention (Colgrove 2006 ) and may even choose procedures for their children that they would not choose for themselves.3 To the extent that both technologies are sup ported, recommended, and even mandated by governments (and allied institutions), they represent biopolitical solutions to contemporary pub lic health quandaries. 
METHODS AND DATA
Our project employs a multisited ethnography approach (Marcus Rapp 1999) , in which multiple sites, sources, actors, and contexts ar ultaneously explored until theoretical saturation is achieved. Ou sources, listed in Table 1 , include primary and secondary literatures ence, medicine, and public health; print and Internet materials prod major medical associations (e.g., Web sites, press releases, policy ments), grassroots groups, and health advocacy organizations; form informal interviews with key biomedical, public health, and activi ures; participant observation at scientific, clinical, and activist confe news media coverage; materials produced by pharmaceutical acto government documents and Web sites.
We analyzed these data using modified grounded theory (Charmaz 2006) , which builds original theoretical arguments from data, as Glaser and Strauss (1967) recommended, but acknowledges that all data and analysts are already situated within social and cultural contexts. Critical to grounded theory methodology is the constant comparative technique through which data are coded, conceptualized, and categorized based on meanings. Analysis proceeds iteratively, moving from simple codes through complex categories that form the basis for theory. From the universe of data collected for our broader project on the politics of HPV, key sources for the current article emerged through comparison of categories specifically related to HPV and circumcision. Documents and sources that explicitly addressed links between HPV and circumcision were prioritized for closer analysis in favor of sources that did not. News media and reports of scien tific studies and clinical trials were especially helpful in this regard.
In addition, we also undertook content analysis of key texts and docu ments, including a detailed analysis of every item (news report, letter to the editor, and editorial) published from 2005 to 2008 in the New York Times and Washington Post that addressed both HIV and circumcision. Follow ing Altheide's (1996) recommendations for such texts, we have combined the techniques of traditional enumerative content analysis, whereby the researcher ensures a systematic investigation by recording the frequency of items in which salient topics appear, with ethnographic techniques that enable the researcher to interpret and explore the subtle meanings of texts in context.
RESPONSES TO THE HPV VACCINE
The HPV vaccine emerged into a dynamic set of cultural conflicts, embodied health movements, and sexual politics. Clinical trials indicate that Merck's Gardasil may prevent up to 70 percent of CCs and that GlaxoSmithKline's Cervarix may also protect against HPV-45 and HPV 31, the third and fourth most common strains (Harper et al. 2006) . Although these strains of HPV also cause anal, penile, and throat cancers-in men as well as women-Merck focused on CC, thereby deflecting attention away from the sexual nature of HPV and from same-sex transmission vectors and reinforcing the widespread tendency to treat sexual health as a wom en's issue (Berer 2008; Kubba 2008; Nack 2008) . Despite the herd immu Yet almost immediately, and in contrast to the circumcision stories analyzed below, media coverage of the HPV vaccine began to focus on the putative dangers to (and from) young women's sexuality. The vaccine is aimed at preadolescent and adolescent girls, with a recommended target age of 10 to 12, because Merck's trials found a stronger immunological response in girls 10 to 15 than in women 16 to 23 and because few girls begin sexual activity, and thus exposure to HPV, before those ages (Ault and Future II Study Group 2007). Numerous media sources, extrapolat ing from comments issued by the conservative organization Focus on the Family in 2005, began labeling the new technology the "promiscuity vac cine," in reference to its imagined capacity to encourage young women to engage in sexual activity. To those who fear that the HPV vaccine will contaminate "innocent" young people by exposing them to sexual knowl edge, the technology backfires, containing HPV and CC only at the price of activating the more frightening scourge of adolescent sexual activity.
Cultural assumptions about youth and gender suggest that (some) young women (white, middle-class, heterosexual, without disabilities) are to be protected, while young men are largely expected, if not outright encouraged, to exercise their sexuality. As feminist scholars have long argued, prophylac tic interventions related to sex-and sexual health-disproportionately tar get young women, in part because women's potential for pregnancy makes their role in reproduction more obvious and more salient (Berer 2008; Nack 2008) . Although U.S. moral conservatives decry adolescent sexual activity in general, their efforts more frequently target girls. Calls to extend HPV vaccination efforts to boys have been rare in the United States (though they have been common in Canada and, to a lesser extent, Great Britain; , were finding HIV rates 50 percent to 60 percent lower among men in the circumcision groups than men in the control groups (Auvert et al. 2005) . Some later analyses found smaller reductions in HIV transmission (Talbott 2007) as well as significant levels of nonsexual transmission (i.e., from contaminated instruments; Brewer et al. 2007 ).
With no AIDS cure in sight and progress stalled on an HIV vaccine, the international public health community greeted the circumcision studies with cautious optimism. At the 2006 International Conference on AIDS, advocates argued that "new HIV infections in men could be substantially reduced and millions of lives saved if [circumcision] were to be intro duced" (British Medical Journal [BMJ] 2006, vol. 333, 409 ). Yet skeptics cautioned that men who believed themselves fully protected by circumci sion might engage in riskier behavior (the disinhibition thesis), stressed the difficulties of generalizing outside African contexts, given regional variations in HIV strains and transmission patterns (primarily via vaginal intercourse in Africa), and emphasized the need to place circumcision in a comprehensive anti-HIV strategy.
Despite initially "refus[ing] to endorse [circumcision] as a prevention tool until more evidence is produced" (BMJ 2006, vol. 333) , by March 2007, WHO and UNAIDS were urging countries with high heterosexually transmitted HIV rates and low circumcision rates to recognize adult male circumcision as "an additional important intervention [in a comprehensive package] to reduce the risk of heterosexually acquired HIV infection in men," provided adequate medical safeguards were available (e.g., avail ability of sterilized instruments; WHO/UNAIDS 2007). Some experts welcomed circumcision as a sexual health intervention that, by targeting men, shifts some of the burden of sexual health from women, even as they continued to worry that, because circumcision is not 100 percent protec tive, women remain exposed to risk (Berer 2007; Sawires et al. 2007) .
When considering how the African findings might translate to the Uni ted States, many in the public health and medical communities expressed a similar mixture of optimism and caution. National Institute of Allergy and Infectious Diseases director Anthony Fauci declared that circumcis ing adult men "could be an important addition to . . . HIV prevention" while noting that "it is not completely protective and must be seen as a powerful addition to . . . other HIV prevention methods" (BMJ 2007, vol. 334, 11) . Other medical professionals contended that recommending cir cumcision in the United States was premature, given "the many differ ences between the underlying HIV epidemics in Africa and the U.S." and lacking evidence that circumcision can prevent HIV transmission between men (a major vector in the United States; Sullivan et al. 2007, e223 wasn't going to be mandatory" and speculated (based on low uptake for HIV vaccination trials) that it would be difficult to recruit Black and Latino men for circumcision "because of everything from news items (18.8 percent of sample) mentioning concerns that African men might engage in "risky" behavior believing themselves to be protected by circumcision, none extended such arguments to circumcised boys (or men) in the United States.
Most major papers published editorials and letters to the editor calling for the expansion of circumcision to combat HIV. Some of these items specified the African context, but many were vague about location-and age of the targeted males-leaving readers to interpret. One New York 
JUXTAPOSITIONS OF CIRCUMCISION AS HIV PREVENTIVE AND THE HPV VACCINE
Despite similarities between circumcision as HIV preventive and HPV vaccination as containment technologies and links made in clinical stud ies, they are seldom explicit/y juxtaposed in public discourse. Several sites of coappearance are therefore worth exploring: international public health discourse, medical research, news coverage, and the anticircumcision acti vist community.6 Even when the technologies are mentioned together, direct links between them (e.g., conceptual, strategic, clinical) are seldom explored. We suggest here that cultural ideas about gender pervade discus sions of each technology, linking them ideologically even where specific clinical and/or physiological links may not be obvious. Likewise, inter pretation of clinical data on overlaps between male circumcision and the HPV vaccine relies on ideas about gender without naming these.
Juxtaposition of the technologies in international public health dis course is exemplified by UNAIDS executive director Peter Piot's 2007 speech to the 17th annual meeting of the International Society for Sexually Transmitted Diseases Research. Piot described "the feminization of the HIV epidemic and ... burden of STIs on women," including HPV and cervical cancer, as the "most important" epidemiologic trend in STIs; called the HPV vaccine "an exciting development from which we will be able to learn a lot ... if and when we have an HIV vaccine"; and noted that "HIV changes the natural history and pattern of STIs," including HPV, by affecting immune suppression (on HIV-HPV links unrelated to circumci sion, see Carpenter and Casper 2009 ). Where Piot did invoke male circum cision, it was to express concern that increasing focus on circumcision is crowding out proven behavioral prevention efforts:
When I was in South Africa ... at the national AIDS conference ... all the discussions were on male circumcision and on microbicides.... There was hardly any discussion about how we can make sure that people today have access to what we know is working [male and female condoms, behavioral interventions]. I think that is a very, very dangerous trend.
The Bill and Melinda Gates Foundation's support for global health ini tiatives likewise encompasses circumcision against HIV and HPV vacci nation without explicitly citing linkages. A major player in global health since its founding in 1994, the Gates Foundation focuses on HIV/AIDS, vaccine-preventable diseases (including HPV), malaria, tuberculosis, and maternal and child health (http://www.gatesfoundation.org). Through its emphasis on supporting "organizations around the world that are using innovative [often technological] methods to improve health in developing countries," the Gates Foundation connects HPV vaccine and circumcision. Center for Journalists to "develop high-impact fellowships in Africa focusing on health issues-including male circumcision and clinical tri als," and $494,474 to UNAIDS to "engag[e] key stakeholders in a dia logue about male circumcision." In September 2007, the Gates Foundation was reported as "expressing interest in helping expand circumcision ser vices in Africa," although "no final decisions" had been made at that time (Washington Post, September 7, 2007) .
Immediately prior to the 2006 World Conference on AIDS, Richard
Feachem, executive director of the Global Fund, was reported as having said research revealing the protective effect of circumcision against HIV was set to change parental expectations and medical practice across the world. Instead of viewing the operation as an assault on the male sex, it was increasingly being seen as a lifesaving procedure which every parent would want for their sons. (Laurance 2006, 15) By early 2007, the Global Fund (along with UNAIDS) had "indicated that they will be willing to pay for circumcisions if countries ask for money and can demonstrate that the operations will be done safely and with the right counseling" (New York Times, March 29, 2007) .
Medical researchers made a more direct connection in March 2009, when New England Journal of Medicine (NEJM) published a study find ing lower rates of HPV infection among circumcised men. Based on clinical trial data from Uganda, authors Tobian et al. (2009 Tobian et al. ( , 1308 esti mated that circumcision reduces transmission of cancer-causing HPV strains by 35 percent (and herpes transmission by 25 percent). Despite noting that reduced HPV rates could result, in part, from the virus naturally clearing over the study period, the authors proposed that "these benefits should guide public health policies for neonatal, adolescent, and adult male circumcision programs" without specifying where. According to the New York Times, coauthor Ron Gray said, "There is no reason to believe that this is in any way unique to Africa" (Bakalar 2009 ). The anticircumcision activist community has also juxtaposed circum cision as HIV preventive and the HPV vaccine. Many participants at the 2008 International Symposium on Genital Integrity, cosponsored by NOCIRC and NORM-UK, argued that circumcision for HIV prevention should be chosen only voluntarily by adult men and can wait until just before men become sexually active, a position consistent with that of activists who propose delaying the HPV vaccine until girls are "older" (i.e., legally capable of consent) and/or sexually active. In informal con versations with author Carpenter, several conference participants explic itly juxtaposed the two technologies, proposing that both could wait until sexual initiation was imminent (albeit arguing that circumcision was never advisable, whereas the HPV vaccine might be). Historically, anticircum cision activists have forcefully countered claims that circumcision pro tects against HPV/CC. According to one Circumcision Information and Resource Pages fact sheet, "Male circumcision has never been proved to offer any real protection against HPV infection in the female partner, but even if it did, it still would not be necessary because the vaccine will offer The sexually transmitted nature of HPV/CC and HIV/AIDS affects responses to the vaccine and circumcision in two ways. First, although HIV can be contracted through injection drug use and other nonsexual means (although chief infection vectors in the United States are sexual), strains of HPV that cause CC are contracted only sexually (unlike strains that cause nongenital warts). The possibility of nonsexual transmission may deflect concerns about disinhibition among circumcised men, as when the (rare) possibility of nonsexual transmission of Hepatitis B helped to forestall seri ous opposition to efforts to mandate that vaccine (J. Colgrove, pers. comm., June 1, 2007) . Thus, the effectiveness of containment metaphors and actual containment strategies may depend on how deeply they are shaped by gen der, race, sexual politics, and notions of bodily transmission. What kinds of fluids and organisms matter as much as which bodies are engaged in "risky" practices. Comparing the "feminized" HPV vaccine to male circumcision brings men's bodies and health into the intersectional mix.
Of course, sexual transmission of disease raises the specter of sexual activity, especially among teenagers and/or outside of marriage, which is generally interpreted quite differently for men and women in most cultural contexts. Our comparative analysis demonstrates how responses to these two technologies have been powerfully shaped by intersections among gen der, sexuality, age, race, and nationality. Attempts to market and mandate the HPV vaccine activated concerns about female promiscuity, whereas talk of promoting circumcision as HIV preventive has not spurred similar con cerns about males in the United States (while men in Africa are treated as suspect). Cultural constructions of gendered sexuality-casting girls and women as either innocent or fallen and boys and men as sexually driven (Nathanson 1991 )-helped proposals to promote circumcision as HIV preventive to escape the association with promiscuity that has dog ged HPV vaccine mandates. Proposals that boys should receive the HPV vaccine to prevent CC in their (ostensibly) female partners-a claim far more common in public discourse than claims about preventing penile and anal cancers in men-invoke (implicitly) feminist notions of "equal opportunity" (for risk and protection) as well as traditional understand ings of men as women's protectors. Conversely, risks and responsibility for circumcision are borne by men alone, and hoped-for benefits to women have not materialized (at least regarding HIV). In fact, men who believe themselves protected by circumcision may be less amenable to partners' requests for safer sex practices. These phenomena reveal and sustain obdurate gender hierarchies.
Understandings of gender and sexuality also intersect with notions about age, race, and nationality. Although U.S. boys have historically been cir cumcised as infants, well before sexual maturity and activity, girls would be vaccinated as preteens on the verge of sexual maturity-a situation that many parents appear to deem far more threatening. Pervasive stereotypes of women and men of color-especially of African descent-as promis cuous not only may inhibit stakeholders' ability to see them as deserving of, or able to benefit from, containment but also may prompt calls for con taining them, as in proposals to target circumcision campaigns at "high risk" men. Both HPV/CC and HIV/AIDS are more widespread and have considerably worse prognosis in the developing world than in the West. Ironically, circumcision is a routine U.S. practice that is now being exp orted to the developing world, whereas the HPV vaccine is desperately needed in the developing world but (potentially) being stalled by conser vative opposition in the United States. By heeding feminist theorists' call for attention to intersectionality, we offer a nuanced analysis of gendered technologies-for women and men-in transnational context. Finally, our analysis reveals that the introduction and/or refraining of these containment technologies is changing cultural understandings of gender, sexuality, race, age, and nationality. Most obviously, the HPV vac cine retrenches gender politics that position young girls simultaneously as sexually innocent (yet likely to fall) and sexually available. The vaccine's use is, in fact, predicated on the eventual fact of girls' sexual activity; conservative resistance to the vaccine rests on fears of adolescent female sexuality unleashed. Conversations about circumcision in the United States show no similar dynamics; indeed, in many instances boys and men are represented as somewhat inert but with the capability of infecting girls and women via heterosexual activity. On the other hand, African men, like gay men and men of African descent in the United States, are routinely framed as dangerously subject to disinhibition. Our analysis highlights the importance of considering how technologies like HPV vaccination and circumcision contribute to the ongoing construction of gender (including "good" and "bad" men and women), race, and sexu ality. It is precisely at these intersections of bodies with technologies that the "double standard" is reproduced. We began by asking why one of these technologies should be embroiled in controversy while the other is relatively free from public debate. We have shown how the politics of sexual health and use of new preventive technologies unfold in a specific cultural context in which containment of bodies, practices, and identities-matters. Intersections of gender (meaning women and men), sexuality, age, race, and nation are critical here. The double standard embodied in and achieved by juxtapositions of HPV vaccination and circumcision has a distinctly American feel while relying on stereotypes about African bodies, sexuality, and transmission. We suggest that technologies are caught up in, and indeed constitute, trans national circuits of power, risk, and prevention as these are enacted on human bodies. Meanings of gender and sexuality shift and change along with bodies and practices while simultaneously grounding the ways in which individuals and societies consider, use, and respond to technologies. NOTES 1. About 2.5 million girls were vaccinated in Gardasil's first year of availabil ity in the United States (Paddock 2008 ).
2. Prior to being adopted by U.S. physicians, around 1870, as a measure for curing and preventing masturbation, cancer, and venereal disease, circumcision was almost exclusively a Jewish ritual practice in the United States (Glick 2006;  Gollaher 2000).
3. Bioethicist and pediatrician Ellen Clayton (pers. comm., numerous dates).
4. Konrad's article is one of the only news stories mentioning the American Academy of Pediatrics review; the organization did not publish a press release on its Web site.
5. However, even the highest estimates of circumcision's effectiveness against HIV are far lower than typical vaccine failure rates of about 5 percent to 10 percent. By comparison, the HPV vaccine failure rate is nearly 0 percent among women never exposed to the virus (see http://www.merck.com/product/usa/pi_ circulars/g/gardasil/gardasil_pi .pdf). 
